2026-05-22T02:48:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/266392025-12-18T12:56:04Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Raposeiras-Roubin, Sergio author Amat-Santos, Ignacio J author Rossello, Xavier author González Ferreiro, Rocío author González Bermúdez, Inmaculada author Lopez Otero, Diego author Nombela-Franco, Luis author Gheorghe, Livia author Diez, Jose L author Baladrón Zorita, Carlos author Baz, José A author Muñoz García, Antonio J author Vilalta, Victoria author Ojeda-Pineda, Soledad author de la Torre Hernández, José M author Cordoba Soriano, Juan G author Regueiro, Ander author Bordes Siscar, Pascual author Salgado Fernández, Jorge author Garcia Del Blanco, Bruno author Martín-Reyes, Roberto author Romaguera, Rafael author Moris, César author García Blas, Sergio author Franco-Peláez, Juan A author Cruz-González, Ignacio author Arzamendi, Dabit author Romero Rodríguez, Nieves author Díez-Del Hoyo, Felipe author Camacho Freire, Santiago author Bosa Ojeda, Francisco author Astorga Burgo, Juan C author Molina Navarro, Eduardo author Caballero Borrego, Juan author Ruiz Quevedo, Valeriano author Sánchez-Recalde, Ángel author Peral Disdier, Vicente author Alegría-Barrero, Eduardo author Torres-Llergo, Javier author Feltes, Gisela author Fernández Díaz, José A author Cuellas, Carlos author Jiménez Britez, Gustavo author Sánchez-Rubio Lezcano, Juan author Barreiro-Pardal, Cristina author Núñez-Gil, Iván author Abu-Assi, Emad author Iñiguez-Romo, Andrés author Fuster, Valentín author Ibáñez, Borja author 2025-04-10 Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials. We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up. A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P = 0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group. Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.). N Engl J Med. 2025 Apr 10;392(14):1396-1405. New England Journal of Medicine 40162639 https://hdl.handle.net/20.500.12105/26639 Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.